DHR
Danaher Corporation NYSE$175.15
After hrs
$174.04
+0.00%
Mkt Cap $124.5B
52w Low $175.00
0.2% of range
52w High $242.80
50d MA $194.30
200d MA $208.86
P/E (TTM)
34.5x
EV/EBITDA
25.3x
P/B
2.4x
Debt/Equity
0.3x
ROE
7.0%
P/FCF
30.8x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$194.30
200d MA
$208.86
Avg Volume
4.4M
About
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterizatio…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | AMC | 1.94 | 2.06 | +6.2% | 194.54 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% | — | — |
| Jan 28, 2026 | AMC | 2.16 | 2.23 | +3.2% | 224.54 | -0.5% | -2.2% | -2.5% | -0.5% | -3.5% | -2.2% | -6.2% | — |
| Oct 21, 2025 | AMC | 1.72 | 1.89 | +9.9% | 220.77 | +0.8% | -1.2% | +0.9% | +1.0% | +0.1% | -1.8% | +0.6% | — |
| Jul 22, 2025 | AMC | 1.64 | 1.80 | +9.8% | 189.91 | +5.6% | +4.2% | +6.8% | +8.2% | +6.9% | +8.9% | +7.4% | — |
| Apr 22, 2025 | AMC | 1.63 | 1.88 | +15.3% | 192.07 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% | -2.4% | — |
| Jan 29, 2025 | AMC | 2.14 | 2.14 | +0.0% | 223.73 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% | -7.1% | — |
| Oct 22, 2024 | AMC | 1.57 | 1.71 | +8.9% | 261.28 | -1.1% | -2.0% | -5.1% | -6.1% | -6.6% | -7.1% | -10.0% | — |
| Jul 23, 2024 | AMC | 1.57 | 1.72 | +9.6% | 264.18 | -0.9% | +0.6% | +2.2% | +3.7% | +2.8% | +4.2% | +1.4% | — |
| Apr 23, 2024 | AMC | 1.72 | 1.92 | +11.6% | 253.11 | -1.6% | -1.1% | -2.9% | -2.6% | -2.5% | -2.6% | +3.3% | — |
| Jan 30, 2024 | AMC | 1.90 | 2.09 | +10.0% | 244.95 | +0.3% | -2.1% | +0.1% | +0.6% | +0.4% | +1.3% | +3.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $184.04 | $180.82 | -1.7% | -3.0% | -3.7% | -1.9% | -2.7% | -2.8% |
| Apr 22 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 22 | Baird | Maintains | Outperform → Outperform | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 22 | Guggenheim | Maintains | Buy → Buy | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 22 | UBS | Maintains | Buy → Buy | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 17 | Baird | Maintains | Outperform → Outperform | — | $193.78 | $194.58 | +0.4% | +0.5% | +0.9% | +0.4% | -5.0% | -7.8% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $195.87 | $195.62 | -0.1% | +1.4% | +1.2% | -1.1% | -0.6% | -0.2% |
| Apr 13 | Goldman Sachs | Maintains | Buy → Buy | — | $189.61 | $188.67 | -0.5% | +3.3% | +4.7% | +4.5% | +2.2% | +2.7% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $191.12 | $190.63 | -0.3% | +0.5% | -0.1% | +2.7% | +1.0% | -0.8% |
| Jan 29 | JP Morgan | Maintains | Overweight → Overweight | — | $224.54 | $223.32 | -0.5% | -2.2% | -2.5% | -0.5% | -3.5% | -2.2% |
Recent Filings
8-K · 7.01
! Medium
Masimo Corporation -- 8-K 7.01: Regulation FD Disclosure
Masimo disclosed material information via press release that investors should review in Exhibit 99.1 for details on developments affecting the company and its parent Danaher.
May 4
8-K
Masimo Corporation -- 8-K Filing
Masimo faces three stockholder lawsuits challenging its merger with Danaher, filed after the definitive proxy statement was disclosed, potentially delaying or jeopardizing the transaction's completion.
Apr 23
8-K
Danaher Corporation -- 8-K Filing
Danaher reported Q1 2026 results from continuing operations, with year-over-year comparisons providing investors insight into the conglomerate's operational performance across its diversified portfolio.
Apr 21
— 8-K filing (BAC, BNPQF, DHR)
Apr 17
8-K · 1.01
! Medium
Danaher Corporation -- 8-K 1.01: Financing / Debt Agreement
Danaher secured a credit facility extending to April 2027 with a one-year extension option available upon 0.50% fee payment, providing financial flexibility for capital management.
Apr 17
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.
Apr 7
8-K · 5.02
!!! Very High
Danaher Corporation -- 8-K 5.02: Executive Change
Danaher's appointment of a new executive signals potential strategic shifts in operations and governance; investors should monitor announcements regarding leadership responsibilities and company direction.
Feb 17
8-K
Danaher Corporation -- 8-K Filing
Danaher's 8-K disclosure likely addresses a material event—possibly an acquisition, dividend change, or executive transition—that could significantly impact earnings, cash flow, or strategic direction, warranting investor review.
Feb 10
Data updated apr 25, 2026 5:10am
· Source: massive.com